Brokerages expect Jounce Therapeutics Inc (NASDAQ:JNCE) to announce sales of $99.97 million for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Jounce Therapeutics’ earnings, with the lowest sales estimate coming in at $85.00 million and the highest estimate coming in at $118.00 million. Jounce Therapeutics posted sales of $14.53 million in the same quarter last year, which would indicate a positive year over year growth rate of 588%. The company is scheduled to issue its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Jounce Therapeutics will report full-year sales of $134.24 million for the current fiscal year, with estimates ranging from $53.00 million to $176.43 million. For the next financial year, analysts forecast that the business will report sales of $84.00 million, with estimates ranging from $50.00 million to $118.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.26) by $0.05. Jounce Therapeutics had a negative net margin of 46.07% and a negative return on equity of 29.64%. The business had revenue of $17.45 million for the quarter, compared to analyst estimates of $17.09 million.

Separately, JPMorgan Chase & Co. restated a “sell” rating on shares of Jounce Therapeutics in a report on Sunday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $10.00.

Shares of JNCE stock traded down $0.09 during trading hours on Monday, reaching $4.02. 4,601 shares of the stock traded hands, compared to its average volume of 320,560. Jounce Therapeutics has a 1-year low of $2.66 and a 1-year high of $8.58. The firm has a fifty day moving average of $4.45. The company has a debt-to-equity ratio of 0.20, a current ratio of 2.03 and a quick ratio of 2.03. The firm has a market capitalization of $141.49 million, a price-to-earnings ratio of -4.81 and a beta of 3.44.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its stake in Jounce Therapeutics by 45.1% in the 4th quarter. Bank of New York Mellon Corp now owns 69,068 shares of the company’s stock worth $233,000 after acquiring an additional 21,475 shares during the last quarter. Raymond James & Associates purchased a new position in Jounce Therapeutics in the 4th quarter worth $71,000. Dimensional Fund Advisors LP raised its stake in shares of Jounce Therapeutics by 5.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 456,865 shares of the company’s stock valued at $1,540,000 after buying an additional 23,153 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Jounce Therapeutics by 14.7% during the 4th quarter. Geode Capital Management LLC now owns 161,421 shares of the company’s stock valued at $543,000 after buying an additional 20,638 shares during the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of Jounce Therapeutics by 28.7% during the 4th quarter. Two Sigma Advisers LP now owns 267,400 shares of the company’s stock valued at $901,000 after buying an additional 59,700 shares during the last quarter. 73.54% of the stock is currently owned by hedge funds and other institutional investors.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform.

Featured Story: How do buyers and sellers choose a strike price?

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.